Question

A 70-year-old with a CDI recurrence within 3 months has risk factors for further recurrence. Which adjunctive therapy should be considered in addition to standard-of-care antibiotics?

Accepted Answer

Bezlotoxumab as a co-intervention to reduce recurrence risk

Answer

No adjunct indicated

Answer

Bezlotoxumab is contraindicated in recurrences

Answer

Probiotics to eradicate C. difficile

Answer

Empiric FMT as first-line

Practice question

A 70-year-old with a CDI recurrence within 3 months has risk factors for further recurrence. Which adjunctive therapy should be considered in addition to standard-of-care antibiotics?